Latest Conference Articles

For the first time in decades, a new regimen — consolidation Imfinzi after chemoradiation — improved outcomes in patients with limited-stage small cell lung cancer.

Rybrevant plus Leclaza had promising response and progression-free survival rates in patients with EGFR-mutant non-small cell lung cancer.

Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.

Rybrevant plus Leclaza outperformed Tagrisso regarding progression-free survival in patients with EGFR-mutant non-small cell lung cancer.

An Adcetris-based treatment regimen improved progression-free survival and was more tolerable for patients with classical Hodgkin lymphoma.

Lorbrena demonstrated longer progression-free survival and improved time to intracranial progression, compared with Xalkori in ALK-positive non-small cell lung cancer.

Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Postmenopausal patients with ovarian or endometrial cancer who received conjugated equine estrogen may have increased mortality rates.

When compared with unvaccinated patients, HPV vaccines were associated with lower rates of HPV-related cancer for people younger than 40.

An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and attend the new appointment.

In a group of breast cancer survivors, 73% who attempted pregnancy were successful, though there were certain characteristics associated with an increased chance of getting pregnant.

Jessica McDade, B.S.N., RN, OCN, explains how she helps make her patients’ experience “a little less daunting” during their hospital stay.

For patients with blood cancers, CAR-T cell therapy has been a “mind-blowing” advancement for treatment in the cancer space.

An expert explained that patients with breast cancer who undergo genetic testing may help their family members, regardless of whether patients have children.

There are a few conversations patients should have with their care teams after being diagnosed with bladder cancer — especially as new treatments become more available.

Slower infusion rates of antiemetic drugs may help manage nausea and vomiting in patients with gastric or gastroesophageal junction cancers.

Welireg outperformed Afinitor in time to disease progression and patient-reported quality of life in the treatment of metastatic clear cell renal cell carcinoma.

Patients with high-risk prostate cancer who had a higher dose of radiation plus long-term androgen deprivation therapy tended to live longer than those who had a lower dose.

Real-world data demonstrated that knowing a patient’s stage and subtype of renal cell carcinoma, a type of kidney cancer, may provide cancer teams with the information needed to determine potential prognosis and recurrence risk.

Subcutaneous Opdivo led to similar outcomes to intravenous administration of the drug and may be easier to access down the road, an expert said.

Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo.

Opdivo failed to improve disease-free survival in patients with localized renal cell carcinoma at high risk of relapse, according to findings from CheckMate 914.

Urinary minimal residual disease-negative status was related to preventing the return of cancer when certain patients with bladder cancer received Adstiladrin.

Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared with the overall population.

Frontline treatment with Keytruda and Cabometyx produced responses with a manageable safety profile in patients with cisplatin-ineligible urothelial carcinoma, a type of bladder cancer.

Nubeqa plus androgen deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer lowered hospitalization rates but led to marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy and docetaxel.

Approximately 40% of patients with metastatic castration-resistant prostate cancer did not undergo certain types of tests that can be instrumental in treatment decisions.

Treatment with Zytiga, prednisone and Erleada plus another treatment regimen improved prostate cancer outcomes and did not change health-related quality of life outcomes.

Lynparza, Zytiga and prednisone led to improved progression-free survival and response rates in patients with metastatic prostate cancer.

Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.